An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Vadimezan (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharma A.G.
- 26 Mar 2022 Status changed from recruiting to completed.
- 28 Jun 2011 New trial record